Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer

Hideya Ohnishi, Takashi Morisaki, Yuji Nakafusa, Yutaka Nakashima, Kazunori Yokohata, Mitsuo Katano

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A 45-year-old woman with HER2(-)/HER1(-) breast cancer underwent radical mastectomy, followed by radiation and chemotherapy. However, her symptoms progressed rapidly owing to meningitis carcinomatosa and she was fitted with a urethral catheter. She also had difficulty in walking. However, immediately after treatment with lapatinib, her symptoms almost completely disappeared. The catheter was removed and she no longer needed a wheelchair. Unfortunately, after treatment was stopped, the bilateral upper limb skin metastases reappeared, the brain metastases relapsed, and she again experienced symptoms of meningitis carcinomatosa. Lapatinib was restarted, resulting in an immediate improvement in the symptoms and a reduction in the skin and brain metastases. Immunohistochemical staining of the lapatinib-sensitive metastatic skin tumor showed it to be HER2(2+), FISH(-)/HER1(-). This result suggested that the lapatinib-sensitive lesions in the brain and meninges were also HER2-positive. Carcinomatosa meningitis has a very poor prognosis and no effective treatment has yet been developed. Here, we report the first case in which lapatinib has been used to effectively treat meningitis carcinomatosa in HER2(-)/HER1(-) relapsed breast cancer.

Original languageEnglish
Pages (from-to)718-721
Number of pages4
JournalInternational Journal of Clinical Oncology
Volume16
Issue number6
DOIs
Publication statusPublished - Dec 1 2011

Fingerprint

Meningitis
Breast Neoplasms
Neoplasm Metastasis
Skin
Brain
Radical Mastectomy
Mobility Limitation
Meninges
Urinary Catheters
Wheelchairs
Upper Extremity
Therapeutics
Catheters
lapatinib
Radiation
Staining and Labeling
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. / Ohnishi, Hideya; Morisaki, Takashi; Nakafusa, Yuji; Nakashima, Yutaka; Yokohata, Kazunori; Katano, Mitsuo.

In: International Journal of Clinical Oncology, Vol. 16, No. 6, 01.12.2011, p. 718-721.

Research output: Contribution to journalArticle

Ohnishi, Hideya ; Morisaki, Takashi ; Nakafusa, Yuji ; Nakashima, Yutaka ; Yokohata, Kazunori ; Katano, Mitsuo. / Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. In: International Journal of Clinical Oncology. 2011 ; Vol. 16, No. 6. pp. 718-721.
@article{e97b45b9c97846c081839665b0f914c2,
title = "Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer",
abstract = "A 45-year-old woman with HER2(-)/HER1(-) breast cancer underwent radical mastectomy, followed by radiation and chemotherapy. However, her symptoms progressed rapidly owing to meningitis carcinomatosa and she was fitted with a urethral catheter. She also had difficulty in walking. However, immediately after treatment with lapatinib, her symptoms almost completely disappeared. The catheter was removed and she no longer needed a wheelchair. Unfortunately, after treatment was stopped, the bilateral upper limb skin metastases reappeared, the brain metastases relapsed, and she again experienced symptoms of meningitis carcinomatosa. Lapatinib was restarted, resulting in an immediate improvement in the symptoms and a reduction in the skin and brain metastases. Immunohistochemical staining of the lapatinib-sensitive metastatic skin tumor showed it to be HER2(2+), FISH(-)/HER1(-). This result suggested that the lapatinib-sensitive lesions in the brain and meninges were also HER2-positive. Carcinomatosa meningitis has a very poor prognosis and no effective treatment has yet been developed. Here, we report the first case in which lapatinib has been used to effectively treat meningitis carcinomatosa in HER2(-)/HER1(-) relapsed breast cancer.",
author = "Hideya Ohnishi and Takashi Morisaki and Yuji Nakafusa and Yutaka Nakashima and Kazunori Yokohata and Mitsuo Katano",
year = "2011",
month = "12",
day = "1",
doi = "10.1007/s10147-011-0195-5",
language = "English",
volume = "16",
pages = "718--721",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer

AU - Ohnishi, Hideya

AU - Morisaki, Takashi

AU - Nakafusa, Yuji

AU - Nakashima, Yutaka

AU - Yokohata, Kazunori

AU - Katano, Mitsuo

PY - 2011/12/1

Y1 - 2011/12/1

N2 - A 45-year-old woman with HER2(-)/HER1(-) breast cancer underwent radical mastectomy, followed by radiation and chemotherapy. However, her symptoms progressed rapidly owing to meningitis carcinomatosa and she was fitted with a urethral catheter. She also had difficulty in walking. However, immediately after treatment with lapatinib, her symptoms almost completely disappeared. The catheter was removed and she no longer needed a wheelchair. Unfortunately, after treatment was stopped, the bilateral upper limb skin metastases reappeared, the brain metastases relapsed, and she again experienced symptoms of meningitis carcinomatosa. Lapatinib was restarted, resulting in an immediate improvement in the symptoms and a reduction in the skin and brain metastases. Immunohistochemical staining of the lapatinib-sensitive metastatic skin tumor showed it to be HER2(2+), FISH(-)/HER1(-). This result suggested that the lapatinib-sensitive lesions in the brain and meninges were also HER2-positive. Carcinomatosa meningitis has a very poor prognosis and no effective treatment has yet been developed. Here, we report the first case in which lapatinib has been used to effectively treat meningitis carcinomatosa in HER2(-)/HER1(-) relapsed breast cancer.

AB - A 45-year-old woman with HER2(-)/HER1(-) breast cancer underwent radical mastectomy, followed by radiation and chemotherapy. However, her symptoms progressed rapidly owing to meningitis carcinomatosa and she was fitted with a urethral catheter. She also had difficulty in walking. However, immediately after treatment with lapatinib, her symptoms almost completely disappeared. The catheter was removed and she no longer needed a wheelchair. Unfortunately, after treatment was stopped, the bilateral upper limb skin metastases reappeared, the brain metastases relapsed, and she again experienced symptoms of meningitis carcinomatosa. Lapatinib was restarted, resulting in an immediate improvement in the symptoms and a reduction in the skin and brain metastases. Immunohistochemical staining of the lapatinib-sensitive metastatic skin tumor showed it to be HER2(2+), FISH(-)/HER1(-). This result suggested that the lapatinib-sensitive lesions in the brain and meninges were also HER2-positive. Carcinomatosa meningitis has a very poor prognosis and no effective treatment has yet been developed. Here, we report the first case in which lapatinib has been used to effectively treat meningitis carcinomatosa in HER2(-)/HER1(-) relapsed breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84855199695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855199695&partnerID=8YFLogxK

U2 - 10.1007/s10147-011-0195-5

DO - 10.1007/s10147-011-0195-5

M3 - Article

VL - 16

SP - 718

EP - 721

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 6

ER -